logo

Arrowhead Pharmaceuticals Inc. (ARWR)



Trade ARWR now with
  Date
  Headline
6/18/2018 7:31:59 AM Arrowhead Completes Enrollment In Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease
5/30/2018 7:38:24 AM Arrowhead Completes Enrollment In Single Dose Portion Of Phase 1/2 Study Of ARO-HBV
5/21/2018 7:35:46 AM Arrowhead Presents New Preclinical Data On ARO-ENaC For Treatment Of Cystic Fibrosis
5/14/2018 7:33:47 AM Arrowhead Doses First Hepatitis B Patients In Multiple Dose Portion Of Phase 1/2 Study Of ARO-HBV
3/28/2018 7:32:22 AM Arrowhead Pharmaceuticals Announces Multiple Presentations At The International Liver Congress
3/27/2018 7:30:43 AM Arrowhead Begins Dosing In Phase 1/2 Study Of ARO-HBV For Chronic Hepatitis B
3/12/2018 7:30:57 AM Arrowhead Commences Dosing In Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease
2/22/2018 7:43:54 AM Arrowhead Gets Regulatory Clearance To Begin Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease
2/15/2018 7:31:39 AM Arrowhead Receives Regulatory Clearance To Begin Phase 1/2 Study Of ARO-HBV For Hepatitis B
2/9/2018 4:03:06 PM Arrowhead Pharma Q1 Loss/share $0.18 Vs. Loss $0.17 Year Ago
1/18/2018 9:10:47 AM Arrowhead Prices Public Offering Of 10 Mln Shares At $5.25 Per Share
1/5/2018 1:21:34 PM B. Riley FBR Starts Arrowhead Pharmaceuticals Inc. (ARWR) At Buy With $3.00 Price Target